An open-label 52-week safety study of bicifadine SR [sustained release] in adult outpatients with chronic peripheral neuropathic pain associated with diabetic peripheral neuropathy.

Trial Profile

An open-label 52-week safety study of bicifadine SR [sustained release] in adult outpatients with chronic peripheral neuropathic pain associated with diabetic peripheral neuropathy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2012

At a glance

  • Drugs Bicifadine (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors XTL Biopharmaceuticals
  • Most Recent Events

    • 18 Sep 2012 Last checked against European Clinical Trials Database (substudy: EudraCT2007-007764-14).
    • 18 Sep 2012 Last checked against European Clinical Trials Database (substudy: EudraCT2007-007764-14).
    • 01 Jul 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top